Preview

Rational Pharmacotherapy in Cardiology

Advanced search

CORRECTION OF ENDOTHELIAL DYSFUNCTION IN PATIENTS WITH CHRONIC COR PULMONALE BY ANGIOTENSIN II RECEPTORS ANTAGONISTS

https://doi.org/10.20996/1819-6446-2007-3-2-48-52

Abstract

Aim. To evaluate intensity of endothelial dysfunction, processes of apoptosis, state of central and peripheral hemodynamics and to evaluate how these characteristics are influenced by angiotensin II receptors antagonists (ARA II) – candesartan (Atacand) and losartan (Cosaar) in patients with chronic cor pulmonale (CCP) at different stages of disease.

Material and methods. 100 patients with chronic obstructive pulmonary disease (COPD), complicated by CCP were included into the study. Caspase activity as apoptosis induction marker, von Willebrand factor, production of nitric oxide in blood plasma and condensate of breathing out air were assessed. 70 patients received ARA II (50 patients – candesartan 4-8 mg daily, 20 patients – losartan 50-100 mg daily), 30 patients received neither ARA II nor angiotensin converting enzyme inhibitors (ACEI).

Results. Significant increase in intensity of endothelial dysfunction and activation of apoptosis processes were registered according to growth of CCP severity. After 6 months of therapy von Willebrand factor decreased by 25,2% and 27,7% in candesartan and losartan groups respectively (p<0.01 for both groups). In the control group only 13.2% of von Willebrand factor reduction was seen.

Conclusion. ARA II added to common therapy of COPD complicated by CCP improves functional state of endothelium restricting hyperproduction of nitric oxide and its toxic effects and slowing down apoptotic cell death.

About the Authors

V. S. Zadionchenko
Moscow State medico-stomatological University
Russian Federation


N. B. Holodkova
Moscow State medico-stomatological University
Russian Federation


O. I. Nesterenko
Moscow State medico-stomatological University
Russian Federation


I. V. Pogonchenkova
Moscow State medico-stomatological University
Russian Federation


A. M. Shchikota
Moscow State medico-stomatological University
Russian Federation


Y. V. Ignatova
Moscow State medico-stomatological University
Russian Federation


I. Y. Malyshev
Research Institute of general pathology and pathophysiology of Russian Academy of Medical Sciences, Moscow
Russian Federation


E. B. Manukhina
Research Institute of general pathology and pathophysiology of Russian Academy of Medical Sciences, Moscow
Russian Federation


S. V. Kruglov
Research Institute of general pathology and pathophysiology of Russian Academy of Medical Sciences, Moscow
Russian Federation


D. A. Pokidyshev
Research Institute of general pathology and pathophysiology of Russian Academy of Medical Sciences, Moscow
Russian Federation


O. A. Zemnina
Research Institute of general pathology and pathophysiology of Russian Academy of Medical Sciences, Moscow
Russian Federation


References

1. Бородина М.А., Мерзликин Л.А., Щетинин В. В. и др. О механизмах развития легочной гипертензии при хронической обструктивной болезни легких. Пульмонология 2003;(3):120-124.

2. Драпкина О.М., Клименков А.В., Ивашкин В.Т. Апоптоз кардиомиоцитов и роль ингибиторов АПФ. Росс кардиол журн 2003; (1):81-6.

3. Маколкин В.И. Нарушение микроциркуляции при сердечной недостаточности. Школа по сердечной недостаточности. Избранные вопросы диагностики и лечения. М., 2000.

4. Малышев И.Ю., Монастырская Е.А. Апоптоз и его особенности в эндотелиальных и гладкомышечных клетках сосудов. В: Дисфункция эндотелия: экспериментальные и клинические исследования. Витебск, 2000. с.4-11.

5. Малышев И.Ю., Монастырская Е.А., Смирин Б.В., Манухина Е.Б. Гипоксия и оксид азота. Вестн Росс акад мед наук 2000;(9):44-8.

6. Ольбинская Л.И., Игнатенко С.Б. Современные представления о патогенезе и лечении хронической сердечной недостаточности. Клин мед 2000;78(8):22-7.

7. Патарая С.А., Преображенский Д.В., Сидоренко Б.А., Масенко В.П. Биохимия и физиология семейства эндотелинов. Кардиология. 2000;(6):78-84.

8. Ребров А.П., Кароли Н.А. Хроническое легочное сердце у больных бронхиальной астмой. Сердечная недостаточность 2002;3(3): 120-3.

9. Федорова Т.А. Хроническое легочное сердце. В: Хронические обструктивные болезни легких. Под ред. Чучалина А.Г. СПб.: Бином, 1998. с.192-216.

10. Arnal JF, Dinh-Xuan AT, Pueyo M, et al. Endothelium-derived nitric oxide and vascular physiology and pathology. Cell Mol Life Sci. 1999;55(8-9):1078-87.

11. Brett SJ, Simon J, Gibbs R, et al. Impairment of endothelium-dependent pulmonary vasodilation in patients with primary pulmonary hypertension. Thorax. 1996;51(1):89-91.

12. Chassagne C, Eddahibi S, Adamy C, et al. Modulation of angiotensin II receptor expression during development and regression of hypoxic pulmonary hypertension. Am J Respir Cell Moll Biol 2000;22:323- 32.

13. Dimmeler S, Herman C, Galle J, Zeicher AM. Upregulation of superoxide dysmutase and nitrig oxide synthesis mediates the apoptosissupressiwe effects of shear on endothelial cells. Arterioscler Thromb Vasc Biol. 1999;19:656-64.

14. Ding Y, Vaziri ND. Nifedipine and diltiazem but not verapamil up-regulate endothelial nitric-oxide synthase expression. J Pharmacol Exp Ther. 2000;292(2):606-9.

15. Dupuis J, Stewart D, Cernacek P, Gosselin G. Human pulmonary circulation is an important site for both clearance and production of en￾dothelin-1. Circulation 1996;94:1578-84.

16. Furchgott RF, Zawadzki JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 1980;288:373-6.

17. He J, Xiao Y, Zhang L. Cocaine induces apoptosis in human coronary artery endothelial cells. J Cardiovasc Pharnacol 2000;35:572-80.

18. Lind L, Granstam SO, Millgard J. Endothelium-dependent vasodilatation in hypertension: a review. Blood Press 2000;9:4-15.

19. Luscher TF, Wenzel RR, Noll G. Local regulation of the coronary circulation in health and disease: role of nitric oxide and endothelin. Eur Heart J 1995;16 Suppl C:51-8.

20. Rossig L, Haendeler J, Hermann C, et al. Nitric oxide down-regulates MKP-3 mRNA levels: involvement in endothelial cell protection from apoptosis. J Biol Chem. 2000;275(33):25502-7.

21. Sagripanti A, Carpi A. Antithrombotic and prothrombotic activities of the vascular endothelium. Biomed Pharmacother 2000; 54(2): 107-11.


Review

For citations:


Zadionchenko V.S., Holodkova N.B., Nesterenko O.I., Pogonchenkova I.V., Shchikota A.M., Ignatova Y.V., Malyshev I.Y., Manukhina E.B., Kruglov S.V., Pokidyshev D.A., Zemnina O.A. CORRECTION OF ENDOTHELIAL DYSFUNCTION IN PATIENTS WITH CHRONIC COR PULMONALE BY ANGIOTENSIN II RECEPTORS ANTAGONISTS. Rational Pharmacotherapy in Cardiology. 2007;3(2):48-52. (In Russ.) https://doi.org/10.20996/1819-6446-2007-3-2-48-52

Views: 1705


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)